A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
NCT06908304Phase 3Recruiting
- Lead sponsor
- Maia Biotechnology (Industry)
- Enrollment
- 300 (estimated)
- Start date
- 8 Dec 2025
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Dec 2027
- Last update posted
- 12 Jan 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- 6-Thio-2'-Deoxyguanosine Drug
- Cemiplimab Drug
- Docetaxel Drug
- Vinorelbine Drug
- Gemcitabine alone Drug
Conditions and primary outcome
- Carcinoma, Non-Small -Cell Lung
Primary outcome
Overall Survival (Within 2 Years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06908304.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06908304 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.